Latest news with #2P
Axios
4 days ago
- Health
- Axios
Off-the-shelf vaccine shows success against deadly cancers
An experimental vaccine targeting one of the most common genetic drivers of hard-to-treat pancreatic and colorectal cancers prevented their recurrence, raising hopes for an "off the shelf" treatment that can train the immune system to attack malignancies. Why it matters: If shown effective in further trials, the vaccine could become a particularly important tool in staving off the return of pancreatic cancer, which sees roughly 80% of surgically removed tumors recur within five years. What they're saying:"This was a trial all of us in the medical oncology world have been waiting for," said Tracy Proverbs-Singh, an oncologist at Hackensack Meridian's John Theurer Cancer Center. "We see these patients for five years, we see the recurrences, we have to re-treat them, and it's devastating. And after we finish chemo, there's not a lot we can do." Go deeper: The peptide vaccine targets the KRAS mutation that occurs in roughly 90% of pancreatic cancers and half of colorectal cancers. Researchers administered the shot, called ELI-002 2P, to 25 patients who'd received conventional treatments but still had small amounts of cancer left in their bodies and were at high risk of relapse. Half of patients had no relapse by 16.3 months, and median overall survival was 28.9 months — both exceeding historical norms, per the study in Nature Medicine. The greatest benefit was seen in patients who had strong T cell responses. At the 20-month mark, 17 of the 25 patients had strong immune responses with 11 of those patients having no recurrence and six having delayed recurrence. The latter successfully underwent further treatment. "All the 17 were still alive which is why we think there's optimistically, something real going on here, because that's much better than what we might have expected historically," said Zev Wainberg, co-director of the UCLA GI Oncology Program and one of the lead authors. Yes, but: Researchers do not yet understand why eight of the 23 patients did not develop a strong immune response as a result of the vaccine. Between the lines: Much of the enthusiasm around therapeutic cancer vaccines has centered on personalized mRNA technology. It is notable that researchers were able to use a non-personalized vaccine because it can be more easily developed at scale. "It's a big shot in the arm for the pancreatic cancer vaccine, which has been elusive in the context of us being able to get something that's effective in the early stages," said Madappa Kundranda, division chief for cancer medicine at Banner MD Anderson Cancer Center. Reality check: This is still a small Phase 1 trial and will require a more robust randomized controlled trial. Wainberg said the team has already completed such a trial and should have results back in 2026. What to watch: Pancreatic cancer, which has a five-year survival rate of around 13% in the U.S., could be treated very differently within the next two years as multiple new drugs targeting the same mutations are also developed.
Argaam
22-06-2025
- Business
- Argaam
2P signs SAR 87.2M contract with Ministry of Commerce
Perfect Presentation for Commercial Services Co. (2P) signed today, June 22, a contract to operate the Unified Call Center for the Ministry of Commerce at a total value of SAR 87.16 million, including VAT. The contract has a duration of 36 months, the company said in a statement to Tadawul. It includes operating, preparing, and developing the ministry's customer service call center. 2P will assign a specialized team to manage inbound and outbound calls and oversee social media communication channels. The team will consist of professional staff to ensure smooth operations and fulfill all center requirements. The project is expected to positively impact the company's financials for 2025, 2026, 2027, and 2028. There are no related parties to the deal, the statement added. 2P previously announced the project award on April 9, 2025, at the same value of SAR 87.16 million, including VAT, according to Argaam 's data.
Argaam
26-05-2025
- Business
- Argaam
2P renews, increases credit facility with SNB to SAR 73.6M
Perfect Presentation for Commercial Services Co. (2P) renewed and increased a Shariah-compliant credit facility to SAR 73.62 million with Saudi National Bank (SNB), the company said in a filing to Tadawul. The facility, secured today, May 26, will be utilized for awarded projects, as well as the issuance of letters of guarantees, credit, and invoice financing. The deal does not have any related parties, 2P said. The financing, available until May 30, 2026, is secured by promissory notes and covers the total amount, according to the statement.
Argaam
20-05-2025
- Business
- Argaam
2P wins SAR 122M maintenance contract in Eastern Health Cluster
Perfect Presentation for Commercial Services Co. (2P) won a SAR 122.2 million contract, inclusive of VAT, to operate and maintain digital health systems at the Eastern Health Cluster, the company said in a statement to Tadawul. The contract covers maintenance, operation, and technical support for computer systems, networks, infrastructure, applications, and storage at the cluster's facilities in the Eastern Province, including King Fahad Specialist Hospital in Dammam. The financial impact is expected to reflect positively from 2025 through 2030. 2P said there are no related parties to the agreement.
Argaam
20-05-2025
- Business
- Argaam
2P hammers out SAR 66.6M deal with NWC
Perfect Presentation for Commercial Services Co. (2P) signed, on May 19, a contract for the operation of the unified contact center, Voice Channels, for National Water Co. (NWC) for SAR 66.63 million, including VAT. In a statement to Tadawul, the company said that the three-year contract entails providing specialized services to establish and operate the unified contact center. This includes managing operations, hiring people, and providing technical solutions and platforms. The contract period is for three contractual years (36 months), and it is expected to have a positive financial effect during 2025, 2026 and 2027.
